The HRH1 Knockout Ca Ski Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population in which the HRH1 gene has been disrupted in the Ca Ski human cervical carcinoma cell line. This polyclonal pool contains a heterogeneous mix of loss-of-function mutations across the target gene, providing a robust model for studying HRH1-dependent signaling without clonal artifacts. As a mixed population, it avoids single-cell bottleneck effects while enabling researchers to assess average phenotypic outcomes of HRH1 disruption in a therapeutically relevant epithelial cancer background.
Ca Ski cells are a widely used adherent epithelial line derived from a metastatic cervical epidermoid carcinoma to the small bowel mesentery. They harbor integrated human papillomavirus type 16 (HPV-16) genomes and serve as a model for HPV-driven cervical carcinogenesis. The cells retain key features of squamous epithelial differentiation and express functional histamine receptors, making them suitable for investigating how histaminergic signals influence tumor cell behavior within the inflammatory microenvironment of HPV-positive cancers.
HRH1 encodes the histamine H1 receptor, a G??q/11-coupled GPCR that transduces extracellular histamine signals into intracellular calcium mobilization and protein kinase C (PKC) activation. Upon ligand binding, HRH1 activates phospholipase C?? (PLC??) to generate inositol trisphosphate (IP3) and diacylglycerol (DAG). IP3 triggers calcium release from endoplasmic stores, while DAG activates PKC, leading to downstream phosphorylation cascades involving Raf, MEK, and ERK, as well as NF-??B nuclear translocation. This signaling axis upregulates expression of pro-inflammatory cytokines (e.g., IL-6, IL-8) and adhesion molecules (e.g., ICAM-1, VCAM-1), processes modulated by regulators such as GRK2, ??-arrestin2, and IL-4.
In the Ca Ski host cell context, HRH1 knockout provides a targeted loss-of-function model to dissect the intersection between histamine signaling and HPV-mediated transformation. Histamine-mediated HRH1 activation may contribute to tumor-promoting inflammation, cell migration, and immune evasion in cervical cancer. By disrupting HRH1, researchers can evaluate how histaminergic pathways influence Ca Ski proliferation, colony formation, cytokine secretion profiles, and responses to antihistamines. This system is particularly relevant for studying allergic inflammation in the tumor microenvironment and for testing biased antagonists that differentially modulate Gq/11 versus ??-arrestin pathways.
Key research applications include calcium flux analyses to quantify HRH1-mediated store-operated calcium entry; NF-??B reporter assays to measure transcriptional responses; RT-qPCR profiling of HRH1-target genes; ELISA-based quantification of secreted IL-8; immunofluorescence tracking of receptor internalization; and migration/invasion studies to assess metastatic potential. The polyclonal format is also well-suited for drug screening campaigns aimed at identifying histamine receptor modulators active in HPV-positive cervical cancer cells. For further technical details or ordering information, please contact Ascent Research.
